中国药科大学学报2026，Vol.57Issue(1)：19-27,9.DOI:10.11665/j.issn.1000-5048.2025031201
基于STING激动剂抗体偶联药物的研究进展
Research advances in STING agonist-based antibody-drug conjugates
摘要
Abstract
Immune-stimulating antibody drug conjugate(ISAC)can not only effectively solve the defects of stimulator of interferon genes(STING)agonists by coupling antibodies with STING agonists through the targeting of antibodies,but also play a synergistic role with antibodies to further improve the efficacy of STING agonists.This review first provides a concise overview of the current research landscape of ISACs and STING agonists,systematically elaborates on evolving trends in STING agonist development,and subsequently summarizes the mechanistic advances in STING ISAC research.Special emphasis is placed on representative STING ISAC candidates in preclinical/clinical development.Finally,the future directions of STING ISACs are critically discussed with perspectives and recommendations,aiming to provide theoretical insights and practical guidance for future investigations.关键词
免疫刺激抗体偶联物/干扰素基因刺激蛋白激动剂/抗体药物偶联物/免疫反应Key words
immune-stimulating antibody drug conjugate/stimulator of interferon genes agonist/antibody drug conjugate/immune response分类
医药卫生引用本文复制引用
张靖,李德鹏,喻彬,李志裕,卞金磊..基于STING激动剂抗体偶联药物的研究进展[J].中国药科大学学报,2026,57(1):19-27,9.基金项目
This study was supported by the National Natural Science Foundation of China(No.82103989) （No.82103989）
and the Natural Science Foundation of Jiangsu Province(BK20242075) 国家自然科学基金项目(No.82103989) （BK20242075）
江苏省自然科学基金项目(BK20242075) （BK20242075）
